Study reports role of cFLIP in breast cancer cells' resistance to TRAIL-induced apopt

[News]

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine and the University of Granada found that cFLIP -an inhibitor of death ligand-induced apoptosis- is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells.

More... (http://www.news-medical.net/news/20101214/Study-reports-role-of-cFLIP-in-breast-cancer-cells-resistance-to-TRAIL-induced-apoptosis.aspx)